A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...

Investors welcomed reports that the next wave of President Trump's tariffs will be more targeted than threatened.

Pharmaceutical giants such as J&J ... More than 56,000 of J&J's 138,000 workers have taken a generative AI training course, which is required before any employee is authorized to use the technology.

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron ...

He expressed reservations about buying shares of Recursion Pharmaceuticals in light of ... He added, "We're going to have to hold off. I gotta meet them face to face and see what's going on." ...

New Jersey's pharmaceutical industry supports 370,000 ... patients in hospitals where we have no other solutions," he said. "So we absolutely want to make sure that this work moves forward." ...

LOS ANGELES, March 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc.

In the last 5 years Fennec Pharmaceuticals saw its revenue grow at 90% per year. That's well above most pre-profit companies. While long-term shareholders have made money, the 7% per year gain over ...

LOS ANGELES, March 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals ...

2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Regeneron Pharmaceuticals ...